Diabetic neuropathy: an insight on the transition from synthetic drugs to herbal therapies

Arora, Komal; Tomar, Pushpa C.; Mohan, Vandana

doi:10.1007/s40200-021-00830-2

Cited by 7 publications

(4 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, axon-glia dysfunction and reduced nerve conduction velocity because of structural degeneration of nerves are also examined. It also causes the downregulation of glutathione reduction pathway which causes the accumulation of free radical and peroxides, thus aggravating the nerve damage and resulting in NO-mediated vasodilation [ 21 ].…”

Section: Metabolic Pathways Of Painful Diabetic Neuropathy (Pdn) and Potential Therapeutic Agentsmentioning

confidence: 99%

An Insight into Potential Pharmacotherapeutic Agents for Painful Diabetic Neuropathy

Qureshi

Ali

Khalid

2022

Journal of Diabetes Research

View full text Add to dashboard Cite

Diabetes is the 4th most common disease affecting the world’s population. It is accompanied by many complications that deteriorate the quality of life. Painful diabetic neuropathy (PDN) is one of the debilitating consequences of diabetes that effects one-third of diabetic patients. Unfortunately, there is no internationally recommended drug that directly hinders the pathological mechanisms that result in painful diabetic neuropathy. Clinical studies have shown that anticonvulsant and antidepressant therapies have proven fruitful in management of pain associated with PDN. Currently, the FDA approved medications for painful diabetic neuropathies include duloxetine, pregabalin, tapentadol extended release, and capsaicin (for foot PDN only). The FDA has also approved the use of spinal cord stimulation system for the treatment of diabetic neuropathy pain. The drugs recommended by other regulatory bodies include gabapentin, amitriptyline, dextromethorphan, tramadol, venlafaxine, sodium valproate, and 5 % lidocaine patch. These drugs are only partially effective and have adverse effects associated with their use. Treating painful symptoms in diabetic patient can be frustrating not only for the patients but also for health care workers, so additional clinical trials for novel and conventional treatments are required to devise more effective treatment for PDN with minimal side effects. This review gives an insight on the pathways involved in the pathogenesis of PDN and the potential pharmacotherapeutic agents. This will be followed by an overview on the FDA-approved drugs for PDN and commercially available topical analgesic and their effects on painful diabetic neuropathies.

show abstract

Section: Metabolic Pathways Of Painful Diabetic Neuropathy (Pdn) and Potential Therapeutic Agentsmentioning

confidence: 99%

An Insight into Potential Pharmacotherapeutic Agents for Painful Diabetic Neuropathy

Qureshi

Ali

Khalid

2022

Journal of Diabetes Research

View full text Add to dashboard Cite

show abstract

“…Curcumin is the component that makes Curcuma longa active. demethoxycurcumin, bisdemethoxycurcumin, and volatile oils are other active ingredients (tumerone, zingiberene, and atlantone) [76,77]. It is renowned for its astounding ability to treat many ailments.…”

Section: Curcuma Longamentioning

confidence: 99%

Keloids: A Review of the Diseases, Causes, and Current Treatments

Anirudh¹,

Gomathi²,

Sujatha³

et al. 2022

JPRI

View full text Add to dashboard Cite

Keloids are benign tumors that grow as a result of excessive collagen release from overexpressed fibroblasts. Keloids and hypertrophic scars are distinguished by the fact that keloids develop beyond the site of the original lesion, but hypertrophic scars do not. It is still unclear why this mechanism operates, mainly when aberrant scarring occurs. Despite several treatments' availability, the keloids' recurrence rate remains high. Here, we summarize recent narrative reviews, systematic reviews, and meta-analyses to give a general overview of the condition, its underlying causes, and available therapies for keloids. To undertake a comprehensive investigation of the disease, over 100 publications were reviewed utilizing Google Scholar and Pubmed. We also shed light on using phytochemicals as a natural alternative to prevent keloid scarring, which occurs when the body responds abnormally to external injuries by producing scar tissue. We also summarize the available current treatments.

show abstract

“…Natural products are considered a promising alternative treatment because they can be applied to the multifaceted lesions of DPN owing to their safety and higher patient compliance [ 11 , 12 , 13 , 14 , 15 ]. Recent studies have reported that widely used plant compounds can improve DPN because of their neuroprotective, antioxidative, and anti-neuroinflammatory effects [ 16 ].…”

Section: Introductionmentioning

confidence: 99%

Comparative Efficacy of East Asian Herbal Formulae Containing Astragali Radix–Cinnamomi Ramulus Herb-Pair against Diabetic Peripheral Neuropathy and Mechanism Prediction: A Bayesian Network Meta-Analysis Integrated with Network Pharmacology

Baek²,

Lee

2023

Pharmaceutics

View full text Add to dashboard Cite

The Astragali Radix–Cinnamomi Ramulus herb-pair (ACP) has been widely used in the treatment of diabetic peripheral neuropathy (DPN) as part of East Asian herbal medicine (EAHM). Eligible randomized controlled trials (RCTs) were identified by searching 10 databases. The outcomes investigated were response rate, sensory nerve conduction velocity (SNCV), and motor nerve conduction velocity (MNCV) in four regions of the body. The compounds in the ACP and their targets of action, disease targets, common targets, and other relevant information were filtered using network pharmacology. Forty-eight RCTs, with 4308 participants, and 16 different interventions were identified. Significant differences were observed in the response rate, MNCV, and SNCV, as all EAHM interventions were superior to conventional medicine or lifestyle modification. The EAHM formula containing the ACP ranked highest in more than half of the assessed outcomes. Furthermore, major compounds, such as quercetin, kaempferol, isorhamnetin, formononetin, and beta-sitosterol, were found to suppress the symptoms of DPN. The results of this study suggest that EAHM may increase therapeutic efficacy in DPN management, and EAHM formulations containing the ACP may be more suitable for improving treatment response rates to NCV and DPN therapy.

show abstract

Diabetic neuropathy: an insight on the transition from synthetic drugs to herbal therapies

Cited by 7 publications

References 87 publications

An Insight into Potential Pharmacotherapeutic Agents for Painful Diabetic Neuropathy

An Insight into Potential Pharmacotherapeutic Agents for Painful Diabetic Neuropathy

Keloids: A Review of the Diseases, Causes, and Current Treatments

Comparative Efficacy of East Asian Herbal Formulae Containing Astragali Radix–Cinnamomi Ramulus Herb-Pair against Diabetic Peripheral Neuropathy and Mechanism Prediction: A Bayesian Network Meta-Analysis Integrated with Network Pharmacology

Contact Info

Product

Resources

About